
Eargo EAR
Quarterly report 2023-Q3
added 11-07-2023
Eargo Interest Expense 2011-2026 | EAR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 549 K | 1.07 M | 1.92 M | 711 K | 424 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.92 M | 424 K | 934 K |
Quarterly Interest Expense Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 549 K | 285 K | 264 K | - | 269 K | 266 K | 263 K | - | 279 K | 877 K | 266 K | - | 218 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 877 K | 218 K | 354 K |
Interest Expense of other stocks in the Medical devices industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
5.8 M | - | 1.37 % | $ 20.5 M | ||
|
Conformis
CFMS
|
2.02 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
-38.2 M | $ 39.27 | -1.36 % | $ 5.85 K | ||
|
Cardiovascular Systems
CSII
|
1.63 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-244 K | - | -10.19 % | $ 1.99 M | ||
|
Acutus Medical
AFIB
|
5.66 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
410 K | - | 14.99 % | $ 929 K | ||
|
Cognyte Software Ltd.
CGNT
|
-1.61 M | $ 7.82 | - | $ 561 M | ||
|
Allied Healthcare Products
AHPI
|
191 K | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
1.19 M | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
232 K | $ 3.99 | - | $ 149 M | ||
|
AdaptHealth Corp.
AHCO
|
-274 K | $ 9.4 | - | $ 1.27 B | ||
|
FONAR Corporation
FONR
|
347 K | $ 18.5 | -0.32 % | $ 121 M | ||
|
Apollo Endosurgery
APEN
|
4.67 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
31.1 M | $ 43.41 | - | $ 1.35 B | ||
|
Electromed
ELMD
|
78 K | $ 23.98 | - | $ 203 M | ||
|
Avinger
AVGR
|
1.72 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
167 K | $ 29.83 | - | $ 1.37 B | ||
|
Apyx Medical Corporation
APYX
|
2.48 M | $ 3.17 | -3.35 % | $ 110 M | ||
|
Axonics Modulation Technologies
AXNX
|
-2.43 M | - | - | $ 3.31 B | ||
|
IRadimed Corporation
IRMD
|
164 K | $ 104.29 | - | $ 1.32 B | ||
|
Accuray Incorporated
ARAY
|
559 K | $ 0.53 | - | $ 54.5 M | ||
|
Neovasc
NVCN
|
133 K | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
664 K | $ 68.43 | -2.62 % | $ 3.73 B | ||
|
Pulmonx Corporation
LUNG
|
256 K | $ 1.53 | - | $ 59.8 M | ||
|
Align Technology
ALGN
|
7.68 M | $ 182.64 | - | $ 13.7 B | ||
|
Medtronic PLC
MDT
|
402 M | $ 96.71 | - | $ 124 B | ||
|
Inari Medical
NARI
|
294 K | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
-13 K | $ 3.68 | - | $ 779 M | ||
|
BIOLASE
BIOL
|
-1 K | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
548 M | $ 113.61 | - | $ 198 B | ||
|
NuVasive
NUVA
|
-21.4 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
-421 K | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
23 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
349 M | $ 73.85 | - | $ 109 B |